| Accession |
PRJCA023373 |
| Title |
Phase II Trial of Taletrectinib in Chinese Patients with ROS1+ NSCLC |
| Relevance |
Medical |
| Data types |
Variation
|
| Organisms |
Homo sapiens
|
| Description |
The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC |
| Sample scope |
Single cell |
| Release date |
2024-03-18 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| No funding support
|
|
NA
|
|
|
|
| External link |
|
| Submitter |
ling
zhang (shfkgcp@163.com)
|
| Organization |
shanghai pulmonary hospital |
| Submission date |
2024-02-01 |
